Biotech

All Articles

Ideaya bags choice on Biocytogen bispecific ADC in $400M offer

.Ideaya Biosciences is betting $400 million in biobucks that a bispecific antibody-drug conjugate (A...

Takeda takes $140M loss on fallen short epilepsy medication, proclaims FDA run

.Our team presently know that Takeda is actually expecting to discover a course to the FDA for epile...

VBI Injections declare insolvency, looks for asset sale

.Immunology biotech VBI Vaccines is veering precariously close to the climax, along with plans to fi...

Celldex anti-cKIT antitoxin lower hives in one more period 2 research study

.It's challenging to muscular tissue in on a space as very competitive as immunology, but Celldex Th...

Boehringer provides to $1.3 B for gate inhibitor biotech

.Boehringer Ingelheim is offering up to $1.3 billion for Nerio Rehabs and a preclinical invulnerable...

Ventyx's last resort for inflammatory med sides in Crohn's failing

.Ventyx Biosciences' Crohn's ailment medicine did certainly not assist individuals obtain remission ...

Cognition's period 2 SHINE records taint Alzheimer's prospect

.Knowledge Rehabs' phase 2 SHINE test has actually taken a few of the radiance off the Alzheimer's d...

BMS axes bispecific months after submitting to run period 3 test

.Bristol Myers Squibb has actually possessed a whiplash change of heart on its own BCMA bispecific T...

Charles Baum takes control of Terremoto as CEO

.Charles Baum, M.D., Ph.D., who managed Mirati Therapeutics' $ 5.8 billion sale to Bristol Myers Squ...

Asarina to close after attempts to partner Tourette's medicine fail

.After communicating to more than 200 firms to companion a Tourette syndrome treatment that revealed...